A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

NCT ID: NCT02690142

Last Updated: 2018-03-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2018-01-10

Brief Summary

The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-035 when administered intravenously and subcutaneously, to healthy volunteers and to psoriasis patients.

Detailed Description

This first in human study with ABY-035 (a novel IL-17A inhibitor (interleukin 17A)) consists of four Parts. Part A consists of a single ascending intravenous dose study with 40 healthy volunteers divided into five dose cohorts. Each group consists of 8 subjects where 6 subjects will receive ABY-035 and 2 will receive placebo. The subjects will be followed for pharmacokinetic and safety assessments up to Day 95 after dosing.

Part B of the study consists of 6 healthy volunteers who will be given a single subcutaneous dose of ABY-035. The subjects will follow the same study visit schedule as Part A.

Part C of the study will include up to 12 moderate-to-severe psoriasis patients who each patient will be given a single intravenous dose of ABY-035. The patients will follow the same study visit schedule as Part A and B.

Part D of the study will include up to 18 psoriasis patients (mild, moderate or severe). Each patient will participate in 3 or 7 biweekly dosing occasions of subcutaneously administered ABY-035. Patients will be followed regularly for safety, efficacy and pharmacokinetics for 8 weeks post-final dose.

Conditions

Psoriasis; Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

ABY-035 i.v.

Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Single dose i.v.

ABY-035 i.v.

Intervention Type: DRUG

Single dose i.v.

ABY-035 s.c.

Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.

Group Type: EXPERIMENTAL

ABY-035 s.c.

Intervention Type: DRUG

Single dose s.c.

ABY-035 i.v. in psoriasis patients

Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.

Group Type: EXPERIMENTAL

ABY-035 i.v.

Intervention Type: DRUG

Single dose i.v.

ABY-035 s.c. in psoriasis patients

Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections

Group Type: EXPERIMENTAL

ABY-035 s.c.

Intervention Type: DRUG

Single dose s.c.

Interventions

Placebo

Single dose i.v.

Intervention Type: DRUG

ABY-035 i.v.

Single dose i.v.

Intervention Type: DRUG

ABY-035 s.c.

Single dose s.c.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Part A, Part B

• Males or females between 18 and 65 years of age
• Body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive. maximum body weight of 120 kg
• In good health, as determined by medical history, physical examination, vital signs assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.
• Subjects will have given their written informed consent to participate in the study

In addition for Part C and D

• Males or females between 18 and 65 years of age
• Body mass index (BMI) between 18.0 kg/m2 and 39.9 kg/m2, inclusive. Minimum body weight of 45 kg
• Part C: Patients must have had a diagnosis of moderate to severe plaque type psoriasis at least 6 months prior to administration of the study drug without a documented flare within 30 days prior to Screening. Patients with concurrent psoriatic arthritis may be enrolled.
• Part D: Patients must have had a diagnosis of plaque type psoriasis (mild, moderate or severe) at least 6 months prior to administration of the study drug without a documented flare within 30 days prior to Screening. Patients with concurrent psoriatic arthritis may be enrolled.
• Part C: Have plaque type psoriasis covering at least 10% of total body surface area (BSA) at Screening and at Baseline (Day 1) and have a PASI score of 12 or greater at Screening and at Baseline (Day 1).
• Part D: Have at least one psoriatic lesion

Exclusion Criteria

Part A, Part B, Part C and Part D

• Subjects who have any clinically significant medical history, as determined by the investigator
• Subjects who smoke more than 15 cigarettes, or equivalent, per day
• Alcohol and/or drug abuse
• Positive for HIV, Hepatitis B, Hepatitis C, or tuberculosis
• Subjects who have received a live vaccination within the 3 months prior to Screening
• Subjects who are pregnant or lactating
• Subjects who do not agree to use appropriate contraception
• Subjects who have a history of anaphylaxis, drug allergy or clinically significant allergic condition (excluding non active hayfever)
• Participation in another clinical trial
• Subjects who, in the opinion of the investigator, should not participate in this study

In addition for Part C and D

• Patients who currently have non plaque forms of psoriasis (eg, erythrodermic, guttate, or pustular)
• Patients who have current drug induced psoriasis
• Have any history of any use of or have participated in clinical trials for any therapeutic agent directly targeted to any IL 17 cytokine or receptor
• Have received phototherapy within 4 weeks prior to Day 1
• Patients who have received systemic medications or treatments that could affect psoriasis or PASI evaluation (including, but not limited to, oral or injectable corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, fumaric acid esters, psoralens, anti TNF (tumour necrosis factor) biologics, anti IL 12/23 biologics, or herbal treatments), within 5 half lives prior to Day 1 (4 weeks for oral anti psoriatics, 12 weeks for psoralens and PUVA (oral psoralen with ultraviolet A), and 24 weeks for biologics)
• Patients who have used topical medications and treatments that could affect psoriasis or PASI evaluation (eg, corticosteroids, coal tar, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen, and trimethyl psoralens) within 2 weeks of administration of IMP (Investigational Medicinal Product)
• Patients who have used any systemic immunosuppressants (eg, methotrexate, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, or tacrolimus) within 8 weeks of administration of IMP (or 5 half lives, whichever is longer).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Covance

INDUSTRY

Sponsor Role: collaborator

Affibody

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sunu Valasseri, MBBS, MSc

Role: PRINCIPAL_INVESTIGATOR

Covance Ltd

Locations

Covance Clinical Research Unit Ltd.

Leeds, , United Kingdom

Covance and Royal Liverpool University Hospital Clinical Research Unit

Liverpool, , United Kingdom

Imperial Centre for Translational and Experimental Medicine Imperial College Healthcare NHS Trust Hammersmith Hospital

London, , United Kingdom

Medicines Evaluation Unit Ltd

Manchester, , United Kingdom

Countries

United Kingdom

References

Klint S, Feldwisch J, Gudmundsdotter L, Dillner Bergstedt K, Gunneriusson E, Hoiden Guthenberg I, Wennborg A, Nyborg AC, Kamboj AP, Peloso PM, Bejker D, Frejd FY. Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs. 2023 Jan-Dec;15(1):2209920. doi: 10.1080/19420862.2023.2209920.

Reference Type: DERIVED

PMID: 37184136 (View on PubMed)

Other Identifiers

2015-004531-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ABY-035-001

Identifier Type: -

Identifier Source: org_study_id